Tiziana Life Sciences () ()'s investment case is presented by Proactive Research Analyst John Savin who explains why the group's recent licensing deal with Precision Biosciences Inc (NASDAQ:DTIL) could become 'a major value add' to Tiziana over the long term.
Savin says Precision Biosciences, Tiziana’s new US partner, is hoping to use foralumab, Tiziana’s clinical-stage fully-human mAb, as a lymphodepletion or ‘tolerising’ agent to improve the long-term success of CAR-T in cancer treatment.
Read Proactive analyst latest update: New use for foralumab in CAR T-cell therapy
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...
FOR OUR FULL DISCLAIMER CLICK HERE